Bleeding Complications of BRAF Inhibitors.

Area of Science:

• Oncology
• Pharmacology
• Vascular Biology

Background:

• BRAF inhibitors are key treatments for BRAF-variant melanoma.
• Clinically significant bleeding events associated with BRAF inhibitors have been reported.
• The mechanism involves paradoxical MAPK activation in endothelium, leading to microvascular leak and potential reduction in procoagulant activity.

Purpose of the Study:

• To review the incidence and mechanisms of bleeding associated with BRAF inhibitors.
• To outline management strategies for patients experiencing bleeding events.
• To discuss considerations for therapy continuation, discontinuation, and rechallenge.

Main Methods:

• Literature review of reported bleeding events in BRAF inhibitor trials.
• Analysis of proposed mechanisms for BRAF inhibitor-induced bleeding.
• Synthesis of current management principles and evidence gaps.

Main Results:

• Bleeding is an uncommon but heterogeneous side effect of BRAF inhibitors, with rare Grade ≥3 events and fatal intracranial hemorrhages.
• BRAF inhibitors may paradoxically activate MAPK signaling in endothelium, destabilizing junctions and causing microvascular leak.
• BRAF inhibitors might also reduce tissue factor-dependent procoagulant activity.

Conclusions:

• Management requires baseline bleeding risk assessment, including CNS disease and antithrombotic use.
• Low-grade bleeds may be managed with local hemostasis and continued therapy, while major/intracranial bleeds necessitate suspension and multidisciplinary input.
• Evidence for rechallenge is limited; resumption after minor events may be possible with dose modification, but major bleeds generally warrant discontinuation.